# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 pri...
Cantor Fitzgerald analyst Louise Chen reiterates PDS Biotechnology (NASDAQ:PDSB) with a Overweight.
Company to Host Key Opinion Leader Event on May 8 at 1:30pm ET to Discuss Updated Results of VERSATILE-002, Unmet Treatment Nee...
B. Riley Securities analyst Kalpit Patel reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target f...
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 pric...